Patients who are receiving conventional therapy according to the MOH protocol.

Patients will receive Liquorice cap and Boswellia Serrata gum in addition to conventional therapy

COVID-19

LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.
Dose:
One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour

Licorice extract

Faculty of Medicine, Assiut University

Complementary Intervention for COVID-19

Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine

Conversion of RT-PCR indicates positive for novel coronavirus RNA to negative

Decrease number of patients that require respiratory support , management in the Intensive Care Unit (ICU) and need Mechanical Ventilation Support with endotracheal intubation.

A pilot study for evaluation of the potential therapeutic effect of food supplement, licorice extract, and Boswellia Serrata gum

Adel Gomaa

Professor of medical pharmacology

Egyptian Biomedical Research Network

Herbal formula treatment PROLUNG in additional to current therapy

Idiopathic Pulmonary Fibrosis

Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):
Huang Qi (Radix Astragali Membranaceus): 2 g
Dan Shen (Radix Salviae Miltiorrhizae): 1 g
Jiang Huang (Rhizoma Curcumae Longae): 1 g
Yin Xing (Semen Gingko Bilobae): 1 g
Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g
Bai He (Bulbus Lilii): 1g
Jin Yin Hua (Flos Lonicerae Japonicae): 1 g
Zi Su Ye (Folium Perillae Frutescentis): 1 g
Yin Yang Huo (Herba Epimedii): 1g

PROLUNG

Queen Mary Hospital

Clinical Trial of Chinese Herbal Medicine for Idiopathic Pulmonary Fibrosis (IPF)

The Effectiveness of an Empirical Chinese Medicine Formulation for Idiopathic Pulmonary Fibrosis: an Open Label Clinical Trial

Annual rate of change in forced expiratory vital capacity (FVC) will serve the primary outcome.

The St. George's Respiratory Questionnaire (SGRQ) will be used to additionally assess respiratory functions.

The 36-Item Short Form Survey (SF-36) is a 36-question questionnaire to assess the quality of life of a participant in terms of physical and mental health.

The WHOQOL-BREF measures the physical and psychological health, the social relationships, and the environment of an individual.

All patients will be monitored for adverse reactions of any kind including but not limited to idiosyncratic allergic reactions to some components of the treatment.

antiasthmatic/cancro

Complementary Intervention for COVID-19

Clinical Trial of Chinese Herbal Medicine for Idiopathic Pulmonary Fibrosis (IPF)

O mais completo banco de dados de ervas medicinais apoiado pela ciência